{"symbol":"REGN","fiscalQuarter":"Q4-2016","reportDate":"2017-02-09","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q4-2016","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 1.91%","keyNumbers":[{"metric":"EPS","actual":"$3.04","expected":"N/A","surprise":"+21.36%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted strong performance in key product areas.","They emphasized ongoing investment in research and development.","The team remains focused on long-term growth despite current market conditions."],"summary":"Overall, management expressed confidence in their product pipeline and future growth. They acknowledged challenges but remain committed to innovation."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance indicates better-than-expected profitability, which likely contributed to the positive stock reaction of 1.91%. Investors may view the earnings beat as a sign of resilience in the company's operations. However, the lack of revenue data and guidance leaves some uncertainty about future performance.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q4 2016 earnings: EPS beat by 21.36%. Stock up 1.91%. Full breakdown."}}